CPT code 88182 denotes a laboratory flow cytometry procedure that analyzes cell cycle or DNA content from specimens such as tumor tissue, body fluid, blood, bone marrow, or urine. This test supports diagnostic and treatment decision-making for malignancies by characterizing DNA content and cell cycle phases. Nationally, flow cytometry assays like this are central to hematology-oncology workups, disease monitoring, and targeted therapy planning.

Key payers relevant to coverage and payment patterns include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for CPT code 88182, an overview of typical sites of service and laboratory workflows, and guidance on the types of benchmarks and policy details commonly reviewed when evaluating this code. This includes reimbursement benchmarks, coding and billing considerations, and payer coverage trends where available. Data not available in the input for specific rates, taxonomies, and ICD-10 mappings is noted as not provided.

This publication is intended to give clinicians, laboratory managers, and revenue-cycle professionals a clear, national-level summary of what CPT code 88182 represents and the practical contexts in which it is used.